Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Pembrolizumab in Combination With ICE Salvage Chemotherapy for Relapsed/Refractory Hodgkin Lymphoma

NCT03077828 is registered in ClinicalTrials.gov with Northwestern University as lead sponsor.

NCT NCT03077828
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03077828 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Pembrolizumab in Combination With ICE Salvage Chemotherapy for Relapsed/Refractory Hodgkin Lymphoma
Lead sponsor
Northwestern University
Phase
Phase 2
Overall status
Unknown status
Start date
April 21, 2017
Completion date
December 31, 2024
Enrollment
43 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

lymphocyte-rich classical hodgkin lymphoma, recurrent lymphocyte-depleted classical hodgkin lymphoma, recurrent mixed cellularity classical hodgkin lymphoma, recurrent nodular sclerosis classical hodgkin lymphoma, refractory lymphocyte-depleted classical hodgkin lymphoma, refractory mixed cellularity classical hodgkin lymphoma, refractory nodular sclerosis classical hodgkin lymphoma